What is Northland Securities’ Forecast for CHRN Q2 Earnings?

ChronoScale Corporation Common Stock (NASDAQ:CHRN) – Equities researchers at Northland Securities issued their Q2 2027 EPS estimates for ChronoScale Corporation Common Stock in a research report issued on Thursday, October 15th. Northland Securities analyst N. Chokshi anticipates that the company will post earnings per share of ($0.07) for the quarter. Northland Securities has an “Outperform” rating and a $32.00 price objective on the stock. Northland Securities also issued estimates for ChronoScale Corporation Common Stock’s Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.11) EPS, FY2027 earnings at ($0.39) EPS, Q1 2028 earnings at ($0.05) EPS, Q2 2028 earnings at ($0.24) EPS, Q3 2028 earnings at ($0.02) EPS, Q4 2028 earnings at $0.16 EPS and FY2028 earnings at ($0.15) EPS.

Separately, Weiss Ratings upgraded shares of ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, October 9th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $19.00.

ChronoScale Corporation Common Stock Trading Up 7.9%

Shares of NASDAQ CHRN opened at $16.05 on Friday. The stock has a market capitalization of $2.34 billion, a P/E ratio of -2.98 and a beta of 0.98. The company has a debt-to-equity ratio of 0.06, a current ratio of 0.51 and a quick ratio of 0.51. The business has a fifty day moving average price of $19.90 and a 200 day moving average price of $18.19. ChronoScale Corporation Common Stock has a 1-year low of $3.50 and a 1-year high of $30.00.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last issued its earnings results on Wednesday, October 14th. The company reported ($0.29) EPS for the quarter. ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%. The company had revenue of $41.48 million for the quarter.

Hedge Funds Weigh In On ChronoScale Corporation Common Stock

A hedge fund recently raised its position in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc grew its holdings in shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN) by 104.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,338 shares of the company’s stock after buying an additional 1,195 shares during the period. Roble Belko & Company Inc owned 0.07% of ChronoScale Corporation Common Stock worth $25,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.42% of the company’s stock.

Key Headlines Impacting ChronoScale Corporation Common Stock

Here are the key news stories impacting ChronoScale Corporation Common Stock this week:

• Positive Sentiment: Northland Securities’ outlook implies significant potential appreciation, with the firm retaining its Outperform rating and $32 target. The analyst forecasts a return to quarterly profitability with $0.16 EPS in Q4 2028, suggesting improving earnings power over time. Northland Securities analyst estimates
• Neutral Sentiment: Northland expects ChronoScale to remain unprofitable across the forecast period, including estimated losses of $0.07 per share in Q2 2027, $0.10 in Q3 2027, $0.39 for fiscal 2027, and $0.15 for fiscal 2028. The estimates indicate a gradual path toward profitability but continued execution risk. ChronoScale earnings estimates
• Negative Sentiment: ChronoScale reported a fiscal first-quarter loss of $0.29 per share on $41.48 million in revenue. Its negative net margin of 135.66% and negative return on equity of 197.81% underscore substantial ongoing losses and may weigh on the stock until growth translates into better profitability. ChronoScale Reports Fiscal First Quarter 2027 Results

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.